Funded Biotechnology Startups in Woburn
Woburn, Massachusetts has generated biotechnology funding activity across a wide range of stages, from a $60K pre-seed for 100XBIO in April 2025 to a $140M…
Woburn, Massachusetts has generated biotechnology funding activity across a wide range of stages, from a $60K pre-seed for 100XBIO in April 2025 to a $140M round for Replimune Group in November 2024. Among the 11 companies listed here, round types span pre-seed, seed, Series A, Series B, post-IPO equity, and multiple filings categorized as series unknown — a mix that reflects both active early-stage formation and larger raises where terms were not publicly reported.
The two most recent closings both occurred in September 2025: Hopewell Therapeutics raised $3M in a venture round and AlpalifeBio closed a $10M Series A. Earlier in 2025, Fieldstone Bio raised a $5M seed in May and Leveragen closed an undisclosed round in July. Neurogastrx holds the dataset's second-largest disclosed raise at $60M (Series B, August 2021). Three companies — Leveragen, Abpro, and Frequency Therapeutics — did not disclose amounts.
Most recent rounds
11 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Woburn biotech companies?
Replimune Group raised the largest disclosed amount at $140M in November 2024, followed by Neurogastrx at $60M (Series B, August 2021) and AlpalifeBio at $10M (Series A, September 2025). All other disclosed rounds in this dataset fall at or below $5M.
Which companies here raised funding most recently?
Hopewell Therapeutics ($3M venture round) and AlpalifeBio ($10M Series A) both closed in September 2025, making them the most recent raises in this dataset. Leveragen also closed a round in July 2025, though no amount was disclosed.
Which companies did not disclose their round sizes?
Leveragen (July 2025), Abpro (November 2024), and Frequency Therapeutics (August 2022) all closed rounds without publicly reporting amounts. Frequency Therapeutics is also the only post-IPO company in this group.
What funding stages are represented across these 11 companies?
The dataset includes pre-seed (100XBIO), seed (Fieldstone Bio), Series A (AlpalifeBio), Series B (Neurogastrx), post-IPO equity (Frequency Therapeutics), and several rounds categorized as series unknown. The prevalence of 'series unknown' filings means confirmed stage data is incomplete for a substantial portion of the list.
How far back does the funding activity in this list go?
The earliest round is Neurogastrx's $60M Series B from August 2021. The dataset then shows a gap before Frequency Therapeutics' post-IPO equity round in August 2022, with activity picking up again through 2023, 2024, and into mid-to-late 2025.
Are there any very early-stage companies in this Woburn biotech group?
100XBIO raised a $60K pre-seed in April 2025, the smallest and earliest-stage round in the dataset. Fieldstone Bio's $5M seed in May 2025 represents the next earliest stage with a disclosed amount, suggesting some new company formation activity in Woburn through early 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.